Compare FNLC & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNLC | XFOR |
|---|---|---|
| Founded | 1864 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.9M | 276.3M |
| IPO Year | 1995 | N/A |
| Metric | FNLC | XFOR |
|---|---|---|
| Price | $27.70 | $4.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $25.20 |
| AVG Volume (30 Days) | 11.0K | ★ 579.8K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | ★ 26.34 | N/A |
| EPS | ★ 3.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,263.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.11 | $0.17 |
| 52 Week High | $30.33 | $6.63 |
| Indicator | FNLC | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 66.78 |
| Support Level | $26.13 | $3.38 |
| Resistance Level | $27.49 | $4.53 |
| Average True Range (ATR) | 0.83 | 0.24 |
| MACD | -0.15 | 0.15 |
| Stochastic Oscillator | 24.17 | 75.79 |
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.